SwitchBot Introduces Mini Robot Vacuum K10+ Pro for Ultimate Corner and Edge Cleaning Experience

TOKYO, Aug. 14, 2024 /PRNewswire/ -- SwitchBot, a rising brand in smart home retrofitting and automation, is excited to announce the launch of Mini Robot Vacuum K10+ Pro, which is a brand-new upgrade of its popular Mini Robot Vacuum K10+ with an Anti-Tangle Rubber Brush, advanced Position Sensitive Detector (PSD) sensor and upgraded suction power reaching up to 3000Pa. It now offers greater corner coverage and even greater power, to set a new standard for mini robot vacuums in the industry, and is still the world's smallest robot vacuum.

Unmatched Corner & Edge Cleaning Performance

SwitchBot Mini Robot Vacuum K10+ Pro is engineered to provide exceptional corner and edge cleaning performance. Its mini size enables it to navigate and clean areas other regular vacuums cannot reach. With a diameter of just 24.8 cm, and a height of 9.2 cm, K10+ Pro effortlessly cleans under dining tables, ergonomic chairs, sofas, bookshelves, and even the narrowest of spaces, alongside other low areas. Meanwhile, its upgraded PSD sensor can detect the edges of walls and corners even more accurately, even alongside table and chair legs, which, combined with an edge brush speed of 200 reps/min, enables K10+ Pro to clean in an even more powerful way.

Comprehensive Environment Perception

K10+ Pro features a LiDAR sensor and a PSD sensor, providing a more precise perception of your home environment. This advanced perception system helps the vacuum navigate obstacles more effectively and reduces collisions. Additionally, the sensitive cliff sensor ensures the vacuum detects edges efficiently so that K10+ Pro won't fall off the edges.

Enhanced Noise Reduction with SilenTechâ„¢

K10+ Pro is equipped with SilenTechâ„¢ technology, reducing noise to just 45dB during silent cleaning mode—quieter than a library. Its comprehensive environment perception system allows it to navigate furniture flexibly, minimizing collisions and creating a naturally even quieter cleaning environment. The Do Not Disturb mode further enhances user comfort by preventing cleaning disturbances during work hours.

Comprehensive Cleaning with Low Maintenance

Equipped with the latest SLAM intelligent navigation, SwitchBot Mini Robot Vacuum K10+ Pro dynamically plans cleaning paths with up to 3000Pa suction power and cleans for up to 150 minutes on a single charge. K10+ Pro also features a unique four-stage cleaning method to consolidate dust and hair together first, raise the dust and hair up from the floors and carpets, vacuum all the dust and hair floating in the air, and then collect everything into its dust box.

Despite its compact size, K10+ Pro comes with a mini base station that features a large 4L dust bag, allowing users to dispose of trash only once every 90 days. This convenience, combined with its powerful suction and long-lasting battery, makes K10+ Pro a top choice for maintaining a clean home effortlessly.

Small Size Yet Flagship Features

Used with SwitchBot Hub 2 or Hub Mini Matter Enabled, K10+ Pro supports Matter and integrates seamlessly with SwitchBot Ecosystem. It offers refined carpet cleaning, avoiding long-haired carpets and boosting vacuum power for short-haired carpets. Additional features include updated voice packs, 4-speed cleaning, obstacle clearance up to 20mm, Anti-Drop technology, Find My Vacuum, Remote Control, and Child Lock.

Pricing and Availability

SwitchBot Mini Robot Vacuum K10+ Pro is now available on SwitchBot Amazon US/UK/CA/DE/FR/IT/ES and SwitchBot's Official Website Store, starting from $419.99/£419.99/€419.99 (MSRP $599.99 / £599.99 / €599.99). 

For more information, visit SwitchBot's official website or follow via Twitter, Instagram, and Facebook.

*Please kindly note that the prices might vary across different countries/regions.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

SwitchBot Introduces Mini Robot Vacuum K10+ Pro for Ultimate Corner and Edge Cleaning Experience

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the Breakthrough Therapy by the FDA for the treatment of stroke.

The Breakthrough Therapy designation stems from the provisions of 《Food and Drug Administration Safety and Innovation Act》. It is designed to expedite the development and regulatory review of drugs for treating serious diseases and addressing significant unmet medical needs. The designation will be beneficial for the drugs to obtain the FDA's guidance in the clinical development, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

The Breakthrough Therapy designation is based on the significant improvement in efficacy metrics demonstrated by the sublingual tablets in a previous clinical study. The data from a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study in China for the treatment of AIS demonstrated that Sanbexin sublingual tablets significantly improved neurological recovery and independent living ability in patients with AIS compared to placebo, meeting the expected efficacy endpoints with a favorable safety profile. JAMA Neurology published the study's key findings online.

The designation will be beneficial for Simcere to obtain the FDA's guidance in the clinical development of Sanbexin sublingual tablets, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

According to a recent article in The Lancet, stroke is the second leading cause of death and disability worldwide, with 12 million new cases and 6.6 million deaths each year. Among them, acute ischemic stroke is the most common type of stroke, accounting for about 70% of all strokes, and constituting a heavy disease burden for all countries around the world. The efficacy of acute ischemic stroke treatment is highly time-dependent. Receiving treatment as early as possible will help patients to improve their disease outcome and avoid disability.

Sanbexin sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual formulation can quickly disintegrate once in contact with the saliva once place under the tongue and can be absorbed into the blood through the sublingual venous plexus, which is expected to increase the flexibility of stroke treatment. Sequential therapy consisting of the marketed Sanbexin concentrated solution for Injection. These two formulae enable patients to receive a complete course of treatment in and outside of the hospital.

On June 28, 2023, the new drug application (NDA) for Sanbexin sublingual tablets in China is accepted by the National Medical Products Administration. The first indication is for the improvement of neurological symptoms, daily activities, and functional impairment due to AIS. Phase I clinical trials for Sanbexin sublingual tablets on healthy volunteers have been completed in the United States.

CONTACT: Haoyun Huang, huanghaoyun@simcere.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration